Clearmind Medicine, a Vancouver-based psychedelic drugs company, and Yissum, the technology transfer company of Hebrew University, have expanded their collaboration through a new patent application.
The companies submitted an international Patent Cooperation Treaty (PCT) application for generation 3.0 psychedelic compounds, their preparation methods, and their use in treating mental disorders. The patent, if approved, would secure intellectual property rights for Clearmind under its exclusive global license agreement with Yissum. The companies aim to develop advanced psychedelic molecules as potential treatments for mental disorders, with plans to seek patent protection in major jurisdictions like the US, Europe, China, and India.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.